Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open-Label, Decentralized Clinical Trial to Evaluate the Efficacy and Safety of Qelbree® in Adults With Attention-Deficit/Hyperactivity Disorder and Mood Symptoms

NCT06185985 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06185985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06185985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open-Label, Decentralized Clinical Trial to Evaluate the Efficacy and Safety of Qelbree® in Adults With Attention-Deficit/Hyperactivity Disorder and Mood Symptoms
Lead sponsor
Supernus Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Completed
Start date
March 25, 2024
Completion date
December 11, 2024
Enrollment
161 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit/hyperactivity disorder